Pliant Therapeutics
NASDAQ: PLRXSouth San Francisco, US · Founded 2015 · Delaware corporation · 3 known investors
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases. The company focuses on understanding integrin biology and molecular mechanisms of pathology to create safer and more effective therapies for patients.
Biotech
Founders & leadership
Pliant Therapeutics was founded in 2015 by Bernard Coulie.
BC
Bernard CoulieFounder
JH
Johannes HullExecutive
EL
Eric LefebvreExecutive
Board
KR
Kevin RaidyBoard director
NE
CH
SB
Suzanne BruhnBoard director
JC
John CurnutteBoard director
HH
Hoyoung HuhBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$162.6M disclosed across 2 rounds · 2018–2019
▶$100.4MraisedMar 2020 · 66 investors · BiotechnologyRule 506(b)
▶$100.4MraisedMar 2020 · 66 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bernard CoulieExecutive Officer, Director
- Barbara HowesExecutive Officer
- Keith CummingsExecutive Officer
- Gayle CrowellDirector
- Smital ShahDirector
- Kevin RaidyDirector
- Charles HomcyDirector
- Neil ExterDirector
- John CurnutteDirector
- Suzanne BruhnDirector
- Hoyoung HuhDirector
- Eric LefebvreExecutive Officer
- Johannes HullExecutive Officer
- Offering amount
- $100.4M
- Amount sold
- $100.4M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$62.1MraisedJul 2018 · 29 investors · BiotechnologyRule 506(b)
▶$62.1MraisedJul 2018 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin RaidyDirector
- Suzanne BruhnDirector
- Johannes HullExecutive Officer
- John CurnutteDirector
- Hoyoung HuhDirector
- Neil ExterDirector
- Bernard CoulieExecutive Officer, Director
- Eric LefebvreExecutive Officer
- Charles HomcyDirector
- Offering amount
- $62.1M
- Amount sold
- $62.1M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall St13 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Companies competing with Pliant Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Pliant Therapeutics do?
- Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases. The company focuses on understanding integrin biology and molecular mechanisms of pathology to create safer and more effective therapies for patients.
- Who founded Pliant Therapeutics?
- Pliant Therapeutics was founded by Bernard Coulie in 2015.
- Who are Pliant Therapeutics's investors?
- Pliant Therapeutics's investors include Menlo Ventures, Agent Capital, Third Rock Ventures.
- How much funding has Pliant Therapeutics raised?
- Pliant Therapeutics has disclosed $162.6M raised across 2 rounds.
- Where is Pliant Therapeutics headquartered?
- Pliant Therapeutics is headquartered in South San Francisco, US.